CA
RXST icon

Continuum Advisory’s RxSight RXST Stock Holding History

Continuum Advisory’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16
Closed -$550 – 1887
2024
Q4 		$550 Hold
16
– – ﹤0.01% 1716
2024
Q3 		$707 Hold
16
– – ﹤0.01% 1712
2024
Q2 		$963 Hold
16
– – ﹤0.01% 1480
2024
Q1 		$983 Buy
+16
New +$785 ﹤0.01% 1469

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Continuum Advisory's RXST Position: Q1 2025 in Review

Continuum Advisory sold out of RxSight (RXST) in Q1 2025, closing a stake of 16 shares — an estimated $550 sold.

Continuum Advisory first reported a position in RXST in Q1 2024 and held it in 4 quarters. The position peaked at $983 in Q1 2024. 192 funds tracked by Wall St. Rank hold RXST as of Q1 2025.

  • Continuum Advisory reported no remaining RxSight position as of Q1 2025 after selling out during the quarter.
  • Continuum Advisory sold 16 RxSight shares in Q1 2025, an estimated $550.
  • Continuum Advisory first reported a position in RxSight in Q1 2024 and held it in 4 quarters.
  • Continuum Advisory's RxSight position peaked at $983 in Q1 2024.
  • 192 funds tracked by Wall St. Rank held RxSight as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.